Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 7/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30171029 | 0.78 | IDO1 (0.54) | ALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL5020146 | 0.78 | HSD17B1 (0.48) | METAP2ALDH1A1HSD17B10DYRK1B | |
| SCHEMBL1822901 | 0.78 | NOTUM (0.33) | — | |
| SCHEMBL5020151 | 0.78 | IDO1 (0.46) | METAP2MEN1NPC1RAB9AKDM4E | |
| SCHEMBL8780977 | 0.78 | NOTUM (0.33) | — | |
| SCHEMBL5020148 | 0.78 | METAP2 (0.46) | METAP2 | |
| SCHEMBL5020277 | 0.78 | IDO1 (0.46) | METAP2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL18664407 | 0.77 | CDK8 (0.44) | ENPP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5020178 | 0.76 | ASIC3 (0.48) | METAP2MEN1MKNK1MKNK2BRD4 | |
| SCHEMBL10018 | 0.76 | SCN4A (0.46) | RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024076155-A1 | NOVEL COMPOUND AS YEATS DOMAIN INHIBITOR | 노보렉스 주식회사 | 2024-04-11 | — | — | WO | disclosed |
| WO-2023101326-A1 | NOVEL COMPOUND AS AUTOTAXIN INHIBITOR AND USE THEREOF | 주식회사 넥스트젠바이오사이언스 | 2023-06-08 | — | — | WO | disclosed |
| EP-3481819-B1 | COMPOUNDS AND THEIR USE FOR REDUCING URIC ACID LEVELS | ACQUIST LLC (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3481819-B1 | COMPOUNDS AND THEIR USE FOR REDUCING URIC ACID LEVELS | ACQUIST LLC (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-109476642-B | Compounds and their use for reducing uric acid levels | 阿奎斯特有限责任公司 | 2022-01-25 | — | — | CN | disclosed |
| US-11161835-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210236495-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210236495-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2021-08-05 | — | — | US | disclosed |
| US-11020397-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-06-01 | — | — | US | disclosed |
| US-11020397-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-06-01 | — | — | US | disclosed |
| US-20140121248-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8623892-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623892-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130184309-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184309-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8389543-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389543-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2012064943-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121248-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | MAP4K4 2023/4885METAP2 60/4885ENPP2 221/4885 |
| US-20210236495-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | MAP4K4 4082/4885METAP2 81/4885ENPP2 636/4885 |
| US-20130184309-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | MAP4K4 2023/4885METAP2 60/4885ENPP2 221/4885 |
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | MAP4K4 2023/4885METAP2 60/4885ENPP2 221/4885 |
| US-11020397-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, UGT2B7 | MAP4K4 4170/4885METAP2 211/4885ENPP2 1431/4885 |
| US-11161835-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | MAP4K4 3972/4885METAP2 96/4885ENPP2 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.